CIK 0001620463
- Non-accelerated filer
- Smaller reporting company
LeonaBio, Inc.
Sign in to watch- Ticker
- LONA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 453368487
- Phone
- +1 425-620-8501
- Business address
- 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL, WA, 98011
- Former names
- Athira Pharma, Inc., M3 Biotechnology, Inc.
- Open-market buys, last 90 days
- $9,919,161,281
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$9,919,161,281. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-03-24 | CHURCH KEVIN Chief Scientific Officer | Exercise or conversion · Stock Option (Right to Buy) | −6,410 | 0 | ||
| 2023-01-27 | Litton Mark James Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +425,000 | 425,000 | ||
| 2023-01-19 | Worthington Mark General Counsel | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2023-01-19 | MOEBIUS HANS Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2023-01-19 | MILESON GLENNA Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2023-01-19 | Lenington Rachel Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2023-01-19 | CHURCH KEVIN Executive VP, Research | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2023-01-05 | Gengos Andrew | Sale | −1,208 | $2.91 | $4K | 83,804 |
| 2023-01-05 | CHURCH KEVIN Chief Scientific Officer | Sale | −2,412 | $2.91 | $7K | 80,256 |
| 2023-01-04 | Gengos Andrew | Grant or award | +5,000 | 85,012 | ||
| 2023-01-04 | CHURCH KEVIN Chief Scientific Officer | Grant or award | +10,000 | 82,668 | ||
| 2022-12-28 | MILESON GLENNA Chief Financial Officer | Purchase | +50,000 | $2.85 | $142K | 159,930 |
| 2022-12-02 | Romano Kelly A Director | Purchase | +30,000 | $3.29 | $99K | 38,315 |
| 2022-11-18 | Litton Mark James Chief Executive Officer | Grant or award | +662 | $2.74 | $2K | 129,217 |
| 2022-11-18 | CHURCH KEVIN Executive VP, Research | Grant or award | +657 | $2.74 | $2K | 62,052 |
| 2022-11-18 | MILESON GLENNA Chief Financial Officer | Grant or award | +763 | $2.74 | $2K | 109,930 |
| 2022-11-15 | MOEBIUS HANS Chief Medical Officer | Purchase | +5,000 | $3.29 | $16K | 65,836 |
| 2022-10-28 | CHURCH KEVIN Executive VP, Research | Exercise or conversion | +3,700 | $1.35 | $5K | 61,395 |
| 2022-10-28 | CHURCH KEVIN Executive VP, Research | Exercise or conversion · Stock Option (Right to Buy) | −3,700 | 6,410 | ||
| 2022-10-13 | MOEBIUS HANS Chief Medical Officer | Exercise or conversion | +7,881 | $1.35 | $11K | 60,836 |
Page 12 of 18 · 349 trades